Global Journal of Medical Research, F: Diseases, Volume 23 Issue 2

14 Year 2023 Global Journal of Medical Research Volume XXIII Issue II Version I ( D ) F © 2023 Global Journals A Cancer Prevention and Treatment Opportunity Target for Cancer. Cells . 2020 Feb 27; 9(3): 561. doi: 10.3390/cells9030561 49. Cole AJ, Fayomi AP, Anyaeche VI, Bai S, Buckanovich RJ. An evolving paradigm of cancer stem cell hierarchies: therapeutic implications. Theranostics . 2020 Feb 10; 10(7): 3083-3098. doi: 10.7150/thno.41647 50. Sevko A, Michels T, Vrohlings M, et al. Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model. J. Immunol . (Baltimore, Md.: 1950). 2013; 190 (5): 2464–7241. doi.org/10.4049/jimmunol.1202781 51. Kotra LP, Paige CJ, Bello AM, Sherman I. Drug complexes comprising alpha-fetoprotein. 2016; Patent WO/2016/119045A1. https://patentimages. storage.googleapis.com/0c/a7/ee/1fd56e9fbcb392/ WO2016119045A1.pdf 52. http://alpha-cancer.com/pre-clinical-studies/act- 901-3-pre-clinical-io-studies 53. Sherman I, Boohaker R, Stinson K, Griffin P, Hill W. An alpha-fetoprotein-maytansine conjugate for the treatment of AFP receptor expressing tumors. J. Clin. Oncol, 40. 2022; no. 16_suppl (June 01, 2022) e15056-e15056. Doi: 10.1200/JCO.2022.40. 16_suppl.e15056 54. Belyaev NN, Abdolla N, Perfilyeva YV, et al. Daunorubicin Conjugated with Alpha-Fetoprotein Selectively Eliminates Myeloid-Derived Suppressor Cells (MDSCs) and Inhibits Experimental Tumor Growth. Cancer Immunol. Immunother . 2018; CII 67 (1): 101–111. doi.org/10.1007/s00262-017-2067-y 55. Zamorina SA, Rayev MB, Cherechnev VA. The use of alpha-fetoprotein in immunopharmacology– history of the subject. Bulletin of Perm University. Biology . 2020; (2), 145–153. Doi: 10.17072/1994- 9952-2020-2-145-153 56. Lin B, Dong X, Wang Q, Li W, Zhu M, Li M. AFP- Inhibiting fragments for drug delivery: the promise and challenges of targeting therapeutics to cancers. Front. Cell Dev. Biol . 2021; 9, 635476. doi.org/10.3389/fcell.2021.635476 57. Gulevskyy OK, Akhatova YuS. Current Concept of the Structural and Functional Properties of Alpha- Fetoprotein and Possibilities of its Clinical Application. 2021; Biotech. Acta . 2021; 14(1): 25-37. doi.org/10.15407/biotech14.01.025 58. Sokol MB, Yabbarov NG, Mollaeva MR, Chirkina MV, Mollaev MD, Zabolotsky AI, et al. Alpha- fetoprotein mediated targeting of polymeric nanoparticles to treat solid tumors. Nanomedicine. 2022; VOL. 17, NO. 18 .doi.org/10.2217/nnm-2022- 0097 59. Hajeri-Germond M, Navalv J, Trojan J & Uriel J. The uptake of alpha-foetoprotein by C-1300 Mouse neuroblastoma cells. Br. J. Cancer (1985), 51, 791- 797. doi: 10.1038/bjc.1985.123 60. Hajeri-Germond M, Naval J, Trojan A, Jay LM, Castillo T, Ly A, Penagos PJ, et al. Diagnostic of CNS neoplasia – AFP and IGF-I targets. In Brain – from development to neoplasia, and gene therapy solution. Ed. Lambert Academic Publisher, Germany, 2017/2018, pp 77-95 -132; ISBN: 978- 620-2-08024-8 61. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res . 2003; Sep 15; 63(18): 5821-8. PMID: 14522905 62. De Leo A, Ugolini A, Veglia F. Myeloid Cells in Glioblastoma Microenvironment. Cells . 2020; Dec 24; 10(1):18. doi: 10.3390/cells10010018 63. Bayik D, Bartels CF, Lovrenert K, Watson DC, Zhang D, Kay K, et al. Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets. Cancer Res . 2022 Nov 15; 82(22): 4274-4287. doi: 10.1158/0008-5472.CAN-21-3840 64. Salemizadeh Parizi M, Salemizadeh Parizi F, Abdolhosseini S, Vanaei S, Manzouri A, Ebrahimzadeh F. Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies. Inflammopharmacology . 2021 Dec; 29(6): 1613-1624). doi: 10.1007/s10787-021- 00878-9 65. Lakshmanachetty S, Cruz-Cruz J, Hoffmeyer E, Cole AP, Mitra SS. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs. Cells . 2021 Apr 14; 10(4): 893. doi: 10.3390/cells10040893 66. Sinha P, Ostrand-Rosenberg S. Withaferin A, a potent and abundant component of Withania somnifera root extract, reduces myeloid-derived suppressor cell function (P2103). J Immunol 1 May 2013; 190 (1_Supplement): 170.8. doi.org/10.4049/ jimmunol.190.Supp.170.8 67. Atteeq M. Evaluating anticancer properties of Withaferin A—a potent phytochemical. Front. Pharmacol . 2022; 13:975320. doi.org/10.3389/ fphar.2022.975320 68. Pak, VN. Alpha-Fetoprotein Binds Toxins and Can Be Used to Treat Cancer. Medical Research Archives, [S.l.], v. 10, n. 10, oct. 2022. ISSN 2375- 1924. doi.org/10.18103/mra.v10i10.3236 69. Pak VN. The possible drug for cancer and metastasis prevention. Future Drug Discovery 2022 4:2. doi.org/10.4155/fdd-2022-0008 70. Pak VN. Compositions of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer. 2006; WO2007056852A1. https://patents.google . com/patent/WO2007056852A1/en 71. Pak VN, Molchanov O, Vincent M. Treatment of Metastatic Colorectal Cancer with Aimpila, a